Biocon: Biosimilars Company Analysis

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.

Features and benefits

• Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
• Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.

Highlights

Biocon's aspirations of expanding from its strong position in the Indian diabetes market were dashed when Pfizer pulled out of an insulin biosimilars deal in March 2012. It remains to be seen to what extent Biocon can continue development alone, or whether a replacement partner will be secured.

Your key questions answered

• Gain an in-depth knowledge of biosimilar strategies on a case study basis.
• Understand how deals and alliances can shape a company’s capabilities in biosimilars.
• Profile leading biosimilars players across a wide cross-section of geographies

Table Of contents

ABOUT THIS REPORT
Chapter structure
Strategic insight
Product analysis
Operating performance
Company introduction
Data sourcing
Analyst consensus
PharmaVitae Explorer database

EXECUTIVE SUMMARY
Biocon biosimilars overview
Biocon biosimilars SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

STRATEGIC INSIGHT
Biocon to extend existing alliances and seek out new partners
Biocon to leverage in-house end-to-end development capabilities

KEY PRODUCTS
Overview
Biocon biosimilar portfolio
Basalog, insulin aspart, and insulin lispro
Overview
Insulin glargine, lispro, and aspart global market size
Key competitors
Biocon biosimilar development
Insugen (human insulin)
Overview
Insulin human market size
Key competitors
Biocon biosimilar development
Erypo (epoetin alfa)
Overview and market size
Key competitors
NUFIL and pegfilgrastim
Overview
Filgrastim and pegfilgrastim market size
Key competitors
Bmab-200 (trastuzumab)
Overview
Trastuzumab market size
Key competitors
Biocon biosimilar development

CORPORATE STRUCTURE
Background
Key corporate developments and company structure
Deals and alliances
Biocon and Pfizer conclude partnership
Biocon and Mylan
Biocon’s other biosimilar-related deals
Recent developments

APPENDIX
References
Datamonitor reports
Exchange rates

List Of Tables

Table: Biocon – biosimilar and novel biologic portfolio
Table: Forecasted lispro, aspart, and glargine insulin sales in the seven major markets and ROW ($m), 2011–16
Table: Biosimilar insulin aspart, insulin glargine, and insulin lispro products currently launched or in development
Table: Biocon – biosimilar insulin glargine clinical trials
Table: Forecasted human insulin sales in the seven major markets and ROW ($m), 2011–16
Table: Biosimilar human insulin products currently launched or in development
Table: Biocon – biosimilar human insulin clinical trials
Table: Forecasted epoetin sales in the seven major markets and ROW ($m), 2011–16
Table: Biocon – pipeline and marketed biosimilar epoetin drugs
Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011–16
Table: Biocon – pipeline and marketed biosimilar filgrastim and pegfilgrastim drugs
Table: Forecasted trastuzumab sales in the seven major markets and ROW ($m), 2011–16
Table: Biosimilar trastuzumab drugs, 2012
Table: Biocon – biosimilar trastuzumab clinical trials
Table: Biocon – biosimilar related deal activities
Table: Exchange rates, 2012

List Of Figures

Figure: The PharmaVitae Explorer
Figure: Biocon biosimilars overview
Figure: Biocon SWOT analysis
Figure: Biocon biosimilars development capabilities
Figure: Biocon – corporate structure